GenSight Biologics

Focus: GenSight Biologics is a Paris-based biotechnology company specializing in ophthalmic gene therapy, with a focused pipeline targeting rare inherited retinal diseases. The company operates in the precision gene therapy space, addressing high unmet medical needs in vision loss disorders.

Gene Therapy Ophthalmology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About GenSight Biologics

AI assessmentNot Hiring

No open roles listed right now. Follow GenSight Biologics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

4 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of

Leber's Hereditary Optic Neuropathy (LHON)

N/A

Clinical Trials (1)

NCT05555784Evaluation of Impact of Disease and Visual Disability on Quality of Life and Loss of Independence of Patients Living in France With Leber's Hereditary Optic Neuropathy (LHON) Through Qualitative and Quantitative Data Collection

N/A

Help build intelligence for GenSight Biologics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Leading position in ophthalmic gene therapy with multiple Phase 3 programs in development, particularly GS010 for Leber's Hereditary Optic Neuropathy
Focused pipeline strategy targeting rare, high-unmet-need diseases with significant commercial opportunity and orphan drug designation potential
Early-stage biotech with meaningful clinical catalysts ahead, offering hands-on involvement in gene therapy development and regulatory milestones

Watch Out For

Currently zero active job openings suggests either a mature hiring cycle or limited near-term headcount expansion, limiting near-term entry points
Pre-revenue status and missing financial data indicates potential cash runway constraints; career stability depends on clinical trial success and future financing

Generated by Claude from GenSight Biologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

GS010

Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber)

N/A

Clinical Trials (1)

NCT03672968EAP_GS010_single Patient

N/A

Patient-reported outcomes

Leber Hereditary Optic Neuropathy

N/A

Clinical Trials (1)

NCT03295071REALITY LHON Registry

N/A